FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed are: composition, which contains β2-agonist, except formoterol and salmoterol, and antagonist of muscarinic receptors M3, which represents 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxy-propyl)-1-azoniumbicyclo[2.2.2]octane in form of salt with anion X, which represents pharmaceutically acceptable anion of mono- or polyvalent acid (aclinidium) and its application for obtaining medication for simultaneous, joined, separate or successive introduction for treatment of respiratory disease, reacting to M3 antagonism (versions), product, set, package, including said combination and respective treatment method.
EFFECT: claimed composition does not give traditional for combination of β2-agonist and antagonist of muscarinic receptors M3 side effects (tachycardia, palpitation, complaints of pains in angina pectoris, arrhythmias) and can be used for treating patient with earlier acquired heart disease or state, which can be aggravated by tachycardia).
19 cl, 4 dwg, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
COMBINATIONS CONTAINING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS | 2005 |
|
RU2404771C2 |
COMBINATIONS CONTAINING ANTIMUSCARINE AGENTS AND CORTICOSTEROIDS | 2005 |
|
RU2385721C2 |
COMBINATIONS CONTAINING ANTI-MUSCARINE PREPARATIONS AND BETA-ADRENERGIC AGONISTS | 2005 |
|
RU2379033C2 |
COMBINATIONS CONTAINING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | 2005 |
|
RU2373935C2 |
COMBINATIONS CONTAINING ANTIMUSCARINE AGENTS AND CORTICOSTEROIDS | 2005 |
|
RU2385156C2 |
COMBINATIONS CONTAINING ANTIMUSCARINIC AGENTS AND INHIBITORS PDE4 | 2005 |
|
RU2404772C2 |
NOVEL METHODS | 2008 |
|
RU2484821C2 |
DERIVATIVES OF QUINUCLIDINEAMIDE, METHOD FOR THEIR PREPARING AND THEIR USING, PHARMACEUTICAL COMPOSITION, COMBINED PRODUCT AND METHOD FOR INHIBITION OF MUSCARINIC RECEPTORS | 2003 |
|
RU2314306C2 |
NOVEL ESTERS OF QUATERNISED QUINUCLIDINE | 2005 |
|
RU2382041C2 |
NOVEL DERIVATIVES OF PYRROLIDINIUM | 2003 |
|
RU2320657C2 |
Authors
Dates
2012-11-10—Published
2010-07-16—Filed